Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
1d
JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback